New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 19, 2012
07:17 EDTCBST, LLY, HSKA, IDXXLeerink to host a conference
November Management Access Days Conference is being held in Boston on November 19-20.
News For LLY;IDXX;HSKA;CBST From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 4, 2016
10:01 EDTIDXXOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AT&T (T) initiated with a Buy at DA Davidson... Abaxis (ABAX) initiated with an Underperform at Credit Suisse... Aratana Therapeutics (PETX) initiated with an Outperform at Credit Suisse... Care.com (CRCM) initiated with an Equal Weight at Morgan Stanley... GCP Applied Technologies (GCP) initiated with a Buy at Jefferies... Heritage-Crystal Clean (HCCI) initiated with a Buy at Roth Capital... IDEXX (IDXX) initiated with an Outperform at Credit Suisse... Nexvet Biopharma (NVET) initiated with an Outperform at Credit Suisse... PetMed Express (PETS) initiated with an Underperform at Credit Suisse... Phibro Animal Health (PAHC) initiated with an Outperform at Credit Suisse... Pure Storage (PSTG) initiated with a Perform at Oppenheimer... SeaWorld (SEAS) initiated with a Neutral at Janney Capital... Seattle Genetics (SGEN) initiated with an Overweight at Barclays... VCA Inc. (WOOF) initiated with an Outperform at Credit Suisse... Verizon (VZ) initiated with a Neutral at DA Davidson... Zoetis (ZTS) initiated with an Outperform at Credit Suisse.
07:42 EDTIDXXIDEXX initiated with an Outperform at Credit Suisse
Subscribe for More Information
February 1, 2016
06:18 EDTLLYTransition Therapeutics announces results from Phase 2 clinical study of TT401
Subscribe for More Information
06:11 EDTLLYTransition Therapeutics reports results from Phase 2 clinical study of TT401
Subscribe for More Information
January 29, 2016
07:07 EDTIDXXIDEXX sees FY16 EPS $2.10-$2.17, consensus $2.13
Sees FY16 revenue $1.69B-$1.71B, consensus $1.71B. Sees FY16 free cash flow to be 95%-100% of net income. Sees FY16 CapEx $90M. Sees FY16 operating margin to be 18%-18.5%, or approximately 100 basis points below 2015 adjusted operating margin levels, driven by ForEx impacts including comparisons to benefits from 2015 hedge gains. Sees FY16 effective tax rate of 30%-30.5%.
07:05 EDTIDXXIDEXX reports Q4 normalized organic revenue growth up 11%
Subscribe for More Information
07:05 EDTIDXXIDEXX reports Q4 adjusted EPS 48c, consensus 44c
Reports Q4 revenue $399.69M, consensus $396.99M.
05:20 EDTLLYEli Lilly, Adocia initiate Phase 1b study of BioChaperone Lispro U100
Adocia and Eli Lilly announced the initiation of a Phase 1b clinical trial evaluating BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Lilly. This formulation uses Adocia's proprietary technology, BioChaperone, which is designed to enable the acceleration of insulin absorption. The study, under the Adocia-Lilly partnership, aims to compare the pharmacokinetic and pharmacodynamic profiles of BioChaperone Lispro to that of Humalog in 15 healthy Japanese subjects placed under euglycemic clamp.
January 28, 2016
09:55 EDTLLYEli Lilly nears test of key support at $80 area
Subscribe for More Information
06:29 EDTLLYEli Lilly backs FY16 adjusted EPS view of $3.45-$3.55, consensus $3.54
Backs FY16 revenue guidance of $20.2B-$20.7B, consensus $20.83B.
06:27 EDTLLYEli Lilly reports Q4 EPS 78c, consensus 78c
Reports Q4 revenue $5.38B, consensus $5.32B.
January 27, 2016
14:44 EDTLLYEli Lilly volatility elevated into Q4 and outlook
Eli Lilly January weekly call option implied volatility is at 54, February is at 29; compared to its 52-week range of 15 to 41, suggesting large near term price movement into the expected release of Q4 results on January 28.
14:34 EDTLLYNotable companies reporting before tomorrow's open
Subscribe for More Information
09:02 EDTLLYEli Lilly and Roche to collaborate on Alzheimer's diagnostic tool
Subscribe for More Information
January 25, 2016
08:36 EDTLLYFDA accepts supplemental NDA for Eli Lilly and Boehringer's Jardiance
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use